The fact that a person for the first time has received a heart transplant from a pig and it was a genetically modified pig made big news this week. Organ transplant waiting lists are a huge problem so if this kind of approach can be proven to be safe and effective, it would be a […]
Recommended reads: pig heart transplant, lasers, $11K pub fee Read More »
The last few years in the stem cell and regenerative medicine arena have been complicated in many ways. Variables like surging stem cell clinics and COVID have made predictions harder. Even so, trying to make predictions is useful and it’s fun to go over past year’s predictions. You can see my scorecard on my 2021
16 predictions for stem cells & regenerative medicine in 2022 Read More »
The amount of biomedical science hype out there is mindboggling at times, but some media or other items really take the cake for being exceptionally bad. Today’s post highlights the worst of the year 2021 as the candidates for my annual The Screamers science hype award. Click on the link in the previous sentence to
The world of stem cell research and regenerative medicine is unpredictable but it’s fun to be a part of it and try to do predictions. Each year in late December or early January I make prognostications for the coming year for stem cell research and regenerative medicine. I made 21 such predictions for the current
Grading my 21 stem cell & regenerative medicine predictions for 2021 Read More »
Part of being a grad student is dealing with technologies related to your projects and their limitations. Sometimes I feel old when I remember the way we used to have to do things in the lab. As a grad student, I manually poured, ran, and read giant sequencing gels. Back then, gene synthesis of a
Weekly reads: grad student life, cell barcoding, diabetes trial, more Read More »
Great ideas and talented scientists are not enough as biomedical research needs funding and here in the U.S. that means having R01 grant success. The trends since 1995 are slowly heading the wrong way. The average age of getting your first R01 grant keeps getting older. There is also still a bit of a possible
Weekly reads: R01 grant trends, DPPA4, adult human neurogenesis debate Read More »
Clade Therapeutics has been pursuing the idea of using gene-editing to make universally compatible cells. The potential here is big. What if you could make cloaked stem cells that could be used to produce cellular therapies that could be given to most patients without fear of immune rejection? Clade Therapeutics Boston Business Journal covers the
Clade Therapeutics pursues universal cells for cancer therapy Read More »
As many of you know I am a cancer survivor myself so studying cancer stem cells has meaning for me on another level. Cancer is also the possible side effect most patients worry about when considering going to an unproven stem cell clinic. I’ve got a new video up on possible stem cell side effects
Weekly reads: cancer stem cells, Bik, & more Read More »
This week marked the release of new draft FDA guidance on cell and gene therapies. Is the FDA kind of like the guidance counselor at school or more like the principal? It probably depends on many factors. I also find it funny how pretty much everyone in academia and biotech industry works to be compliant
Weekly reads: New FDA guidance, brains, MSCs, senescence Read More »
The news of the week relates to an interim clinical trial report from gene-editing firm Editas on its CRISPR trial for a form of vision loss. On to that in a minute. What have you been reading the past week? Below, I include our weekly list of recommended reads. However, first I wanted to give
The Niche weekend reads: Editas mess, The Niche updates, papers Read More »